HK1042247B - 苯並氮雜䓬-n-乙酸衍生物在製備治療肺高血壓的藥物中的應用 - Google Patents

苯並氮雜䓬-n-乙酸衍生物在製備治療肺高血壓的藥物中的應用 Download PDF

Info

Publication number
HK1042247B
HK1042247B HK02104121.2A HK02104121A HK1042247B HK 1042247 B HK1042247 B HK 1042247B HK 02104121 A HK02104121 A HK 02104121A HK 1042247 B HK1042247 B HK 1042247B
Authority
HK
Hong Kong
Prior art keywords
hypertension
alkyl
benzazepine
group
substituted
Prior art date
Application number
HK02104121.2A
Other languages
English (en)
Chinese (zh)
Other versions
HK1042247A1 (en
Inventor
M‧R‧威尔金斯
M‧R‧威爾金斯
D‧索马兰
H‧沃尔戴克
D‧索馬蘭
H‧沃爾戴克
Original Assignee
索尔瓦药物有限公司
索爾瓦藥物有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 索尔瓦药物有限公司, 索爾瓦藥物有限公司 filed Critical 索尔瓦药物有限公司
Publication of HK1042247A1 publication Critical patent/HK1042247A1/xx
Publication of HK1042247B publication Critical patent/HK1042247B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
HK02104121.2A 1999-02-16 2000-02-10 苯並氮雜䓬-n-乙酸衍生物在製備治療肺高血壓的藥物中的應用 HK1042247B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19906310.9 1999-02-16
DE19906310A DE19906310A1 (de) 1999-02-16 1999-02-16 Arzneimittel zur Behandlung von Bluthochdruck
PCT/EP2000/001068 WO2000048601A1 (de) 1999-02-16 2000-02-10 Arzneimittel zur behandlung von bluthochdruck

Publications (2)

Publication Number Publication Date
HK1042247A1 HK1042247A1 (en) 2002-08-09
HK1042247B true HK1042247B (zh) 2005-09-23

Family

ID=7897580

Family Applications (1)

Application Number Title Priority Date Filing Date
HK02104121.2A HK1042247B (zh) 1999-02-16 2000-02-10 苯並氮雜䓬-n-乙酸衍生物在製備治療肺高血壓的藥物中的應用

Country Status (28)

Country Link
US (1) US6482820B2 (cg-RX-API-DMAC7.html)
EP (1) EP1154777B1 (cg-RX-API-DMAC7.html)
JP (1) JP2002537258A (cg-RX-API-DMAC7.html)
KR (2) KR100797665B1 (cg-RX-API-DMAC7.html)
CN (1) CN1198619C (cg-RX-API-DMAC7.html)
AR (1) AR036864A1 (cg-RX-API-DMAC7.html)
AT (1) ATE295174T1 (cg-RX-API-DMAC7.html)
AU (1) AU773240C (cg-RX-API-DMAC7.html)
BR (1) BR0008260A (cg-RX-API-DMAC7.html)
CA (1) CA2362273C (cg-RX-API-DMAC7.html)
CZ (1) CZ301499B6 (cg-RX-API-DMAC7.html)
DE (2) DE19906310A1 (cg-RX-API-DMAC7.html)
DZ (1) DZ3014A1 (cg-RX-API-DMAC7.html)
ES (1) ES2238268T3 (cg-RX-API-DMAC7.html)
HK (1) HK1042247B (cg-RX-API-DMAC7.html)
HU (1) HUP0105491A3 (cg-RX-API-DMAC7.html)
IL (1) IL144622A (cg-RX-API-DMAC7.html)
NO (1) NO329588B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ514058A (cg-RX-API-DMAC7.html)
PL (1) PL195283B1 (cg-RX-API-DMAC7.html)
PT (1) PT1154777E (cg-RX-API-DMAC7.html)
RU (1) RU2270679C2 (cg-RX-API-DMAC7.html)
SK (1) SK287254B6 (cg-RX-API-DMAC7.html)
TR (1) TR200102386T2 (cg-RX-API-DMAC7.html)
TW (1) TWI221770B (cg-RX-API-DMAC7.html)
UA (1) UA63032C2 (cg-RX-API-DMAC7.html)
WO (1) WO2000048601A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200105828B (cg-RX-API-DMAC7.html)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19932555A1 (de) * 1999-07-13 2001-01-18 Solvay Pharm Gmbh Arzneimittel mit protektiver Wirkung gegen oxidativ-toxische und insbesondere gegen kardiotoxische Substanzen
WO2001036610A1 (en) * 1999-11-19 2001-05-25 Solvay Pharmaceuticals B.V. Human enzymes of the metalloprotease family
IL145684A (en) * 2000-10-04 2007-06-17 Warner Lambert Co Medications for the treatment of pulmonary hypertension
AR039352A1 (es) * 2001-05-18 2005-02-16 Solvay Pharm Gmbh Uso de un compuesto que tiene actividad inhibitoria combinada y concurrente con endopeptidasa neutra y metaloproteasa igs5.
CN100519561C (zh) * 2001-09-10 2009-07-29 泰博特克药品有限公司 制备六氢-呋喃并[2,3-b]呋喃-3-醇的方法
IL162645A0 (en) 2002-01-16 2005-11-20 Solvay Pharm Bv solid salts benzazepine compounds and their use inthe preparation of pharmaceuticals compounds
AR038681A1 (es) * 2002-02-14 2005-01-26 Solvay Pharm Bv Formulacion oral de solucion solida de una sustancia activa pobremente soluble en agua
WO2004062692A1 (en) * 2003-01-13 2004-07-29 Solvay Pharmaceuticals B.V. Formulation of poorly water-soluble active substances
US7452875B2 (en) 2003-09-26 2008-11-18 Solvay Pharmaceuticals Gmbh Amidomethyl-substituted 1-(carboxyalkyl) cyclopentyl-carbonylamino-benzazepine-N-acetic acid compounds, process and intermediate products for their preparation and pharmaceutical compositions containing them
US7262184B2 (en) 2003-09-26 2007-08-28 Solvay Pharmaceuticals Gmbh Amidomethyl-substituted 1-(carboxyalkyl) cyclopentyl-carbonylamino-benzazepine-N-acetic acid compounds, process and intermediate products for their preparation and pharmaceutical compositions containing them
SA04250283B1 (ar) * 2003-09-26 2008-05-26 سولفاي فارماسيتيكالز جي أم بي أتش مشتقات من amidomethy1-substituted1-(carboxyalkyl)-cyclopentylcarbonylamino-benzazepine-N-acetic acid
US7427611B2 (en) 2003-09-26 2008-09-23 Solvay Pharmaceuticals Gmbh Amidomethyl-substituted 1-(carboxyalkyl)-cyclopentyl-carbonylamino-benzazepine-N-acetic acid compounds, process and intermediate products for their preparation and pharmaceutical compositions containing them
AR046454A1 (es) * 2003-11-18 2005-12-07 Solvay Pharm Gmbh Uso de un compuesto de acido benzazepin-n-acetico, composicion farmaceutica, y procedimiento para la produccion de dicha composicion farmaceutica
US20050267124A1 (en) * 2004-05-14 2005-12-01 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions comprising NEP-inhibitors, inhibitors of the endogenous producing system and PDEV inhibiitors
US20050267072A1 (en) * 2004-05-14 2005-12-01 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions containing dually acting inhibitors of neutral endopeptidase for the treatment of sexual dysfunction
US20050288272A1 (en) * 2004-06-23 2005-12-29 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions comprising NEP-inhibitors, inhibitors of the endogenous endothelin producing system and AT1 receptor antagonists
US7816347B2 (en) 2004-12-15 2010-10-19 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions comprising NEP-inhibitors, inhibitors of the endogenous endothelin producing system and HMG CoA reductase inhibitors
US20060205625A1 (en) * 2005-02-18 2006-09-14 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions comprising NEP-inhibitors, inhibitors of the endogenous endothelin producing system and diuretics
US20070292503A1 (en) * 2006-06-16 2007-12-20 Gorissen Henricus R Oral pharmaceutical composition of poorly water-soluble active substance
US20070299054A1 (en) * 2006-06-22 2007-12-27 Rajesh Jain Oral pharmaceutical composition of a poorly water-soluble active agent
KR20170005155A (ko) * 2008-01-31 2017-01-11 반더빌트유니버시티 폐의 용태에 따른 치료 방법

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4749688A (en) * 1986-06-20 1988-06-07 Schering Corporation Use of neutral metalloendopeptidase inhibitors in the treatment of hypertension
EP0254032A3 (en) * 1986-06-20 1990-09-05 Schering Corporation Neutral metalloendopeptidase inhibitors in the treatment of hypertension
CA1337400C (en) * 1987-06-08 1995-10-24 Norma G. Delaney Inhibitors of neutral endopeptidase
US5087702A (en) * 1991-01-30 1992-02-11 Merck & Co., Inc. Microbial transformation process for producing an antihypertensive product
US5362727A (en) * 1993-07-26 1994-11-08 Bristol-Myers Squibb Substituted azepino[2,1-a]isoquinoline compounds
DE19510566A1 (de) * 1995-03-23 1996-09-26 Kali Chemie Pharma Gmbh Benzazepin-, Benzoxazepin- und Benzothiazepin-N-essigsäurederivate sowie Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
DE19638020A1 (de) * 1996-09-18 1998-03-19 Solvay Pharm Gmbh Die gastrointestinale Durchblutung fördernde Arzneimittel

Also Published As

Publication number Publication date
TR200102386T2 (tr) 2002-01-21
DE19906310A1 (de) 2000-08-17
PL195283B1 (pl) 2007-08-31
AU773240C (en) 2004-11-18
CZ20012672A3 (cs) 2002-02-13
BR0008260A (pt) 2001-11-06
HUP0105491A3 (en) 2002-08-28
CZ301499B6 (cs) 2010-03-24
ES2238268T3 (es) 2005-09-01
RU2270679C2 (ru) 2006-02-27
PT1154777E (pt) 2005-07-29
TWI221770B (en) 2004-10-11
NO20013958L (no) 2001-10-15
CA2362273A1 (en) 2000-08-24
SK10822001A3 (sk) 2002-03-05
US20020052361A1 (en) 2002-05-02
DE50010284D1 (de) 2005-06-16
CN1198619C (zh) 2005-04-27
KR20010101922A (ko) 2001-11-15
SK287254B6 (sk) 2010-04-07
ZA200105828B (en) 2002-07-15
UA63032C2 (en) 2004-01-15
IL144622A (en) 2006-08-20
PL350167A1 (en) 2002-11-18
AU773240B2 (en) 2004-05-20
CN1339966A (zh) 2002-03-13
US6482820B2 (en) 2002-11-19
NO20013958D0 (no) 2001-08-15
AR036864A1 (es) 2004-10-13
HK1042247A1 (en) 2002-08-09
CA2362273C (en) 2010-05-25
AU2547600A (en) 2000-09-04
EP1154777A1 (de) 2001-11-21
NO329588B1 (no) 2010-11-15
JP2002537258A (ja) 2002-11-05
WO2000048601A1 (de) 2000-08-24
ATE295174T1 (de) 2005-05-15
EP1154777B1 (de) 2005-05-11
DZ3014A1 (fr) 2004-03-27
HUP0105491A2 (en) 2002-06-29
KR100797665B1 (ko) 2008-01-23
NZ514058A (en) 2001-09-28
KR20070027719A (ko) 2007-03-09

Similar Documents

Publication Publication Date Title
HK1042247A1 (en) Use of benzazepine-n ethanoic acid derivatives for perparation of medicament for treating pulmonary hypertension
CN1196479C (zh) 吸入形式的苯并茚前列腺素制剂的用途
JPH09505809A (ja) ヒドロキシカルバゾール化合物類による平滑筋移動および増殖の阻害
JP2002539257A (ja) 薬剤の脳内生物学的利用率の増加
CN1228698A (zh) 含有噻吩并吡啶衍生物和HMG-CoA还原酶抑制剂的抗血栓形成和抗动脉粥样硬化的药物组合
JP2002537258A5 (cg-RX-API-DMAC7.html)
CN1878557A (zh) 用于治疗尤其是在糖尿病患者中的肾的功能障碍、疾病或者病症的药物组合物
CN1068737A (zh) 抗高血压的复合制剂
KR20100084687A (ko) 3-(2,2,2-트리메틸히드라지늄)프로피온산 염의 새로운 의약 용도
USRE34756E (en) Excretion of potassium ion by prostanoic acid derivatives
US5126372A (en) Excretion of nonprotein nitrogen into the intestine by prostanoic acid derivatives
JP4784037B2 (ja) 塩酸ランジオロールを含有する頻脈性不整脈の治療剤
JP2010248263A (ja) 塩酸ランジオロールを含有する頻脈性不整脈の治療剤
MXPA01008164A (en) Medicament for treating hypertension
CN1079233C (zh) 治疗心血管病和良性前列腺增生的药物组合物
JP2949366B2 (ja) 心臓疾患の予防または治療剤
GB2319961A (en) Pharmaceutical composition for treatment of restenosis
HK1026635A (en) Preventives for ischemic heart diseases
JP2000191535A (ja) 血管平滑筋細胞増殖に起因する疾患用薬
CN86103728A (zh) 制备降低血液胆固醇的药剂的方法
JPH03163023A (ja) 腸内排泄剤

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20120210